Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaJohn C. Byrd, Susan O’Brien, Richard R. Furman et al.|New England Journal of Medicine|2013Cited by 2.2k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaJohn C. Byrd, Peter Hillmen, Florence Cymbalista et al.|New England Journal of Medicine|2014Cited by 1.6k
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyMichael J. Keating, Ian W. Flinn, Vinay Jain et al.|Blood|2002Cited by 946
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaNeil E. Kay, John C. Byrd|Blood|2006Cited by 293
Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage PropertiesSarwish Rafiq, John C. Byrd|The Journal of Immunology|2013Cited by 93